Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 167

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Lafora disease — from pathogenesis to treatment strategies

Open access
Nitschke, Felix, Ahonen, Saija J., Nitschke, Silvia, Mitra, Sharmistha, Minassian, Berge A. · 2018 · Nature Reviews Neurology

Abstract

Lafora disease is a severe, autosomal recessive, progressive myoclonus epilepsy. The disease usually manifests in previously healthy adolescents, and death commonly occurs within 10 years of symptom onset. Lafora disease is caused by loss-of-function mutations in EPM2A or NHLRC1, which encode laforin and malin, respectively. The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies. Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease. The integration of current knowledge on the function of laforin–malin as an interacting complex suggests that laforin recruits malin to parts of glycogen molecules where overly long glucose chains are forming, so as to counteract further chain extension. In the absence of either laforin or malin function, long glucose chains in specific glycogen molecules extrude water, form double helices and drive precipitation of those molecules, which over time accumulate into Lafora bodies. In this article, we review the genetic, clinical, pathological and molecular aspects of Lafora disease. We also discuss traditional antiseizure treatments for this condition, as well as exciting therapeutic advances based on the downregulation of brain glycogen synthesis and disease gene replacement.Lafora disease is an autosomal recessive, progressive myoclonus epilepsy caused by loss of function of laforin or malin, leading to impaired glycogen metabolism. The authors review the clinical and molecular features of Lafora disease and discuss current and emerging treatment options.Key pointsLafora disease, a lethal, autosomal recessive, progressive myoclonus epilepsy, is caused by loss-of-function mutations in EPM2A or NHLRC1, which encode laforin and malin, respectively.A large variety of pathogenic variants in EPM2A and NHLRC1 exists, with even distribution across both genes; variants include missense, nonsense and frameshift mutations, as well as larger deletions.Laforin and malin are implicated in glycogen metabolism and are presented as part of a glycogen quality control mechanism, which decreases the risk of precipitation of individual glycogen molecules.In the absence of a functional laforin–malin complex, structurally abnormal glycogen becomes insoluble and accumulates as Lafora bodies, which drive disease progression in the brain.The lack of curative treatments and the current understanding of pathogenesis are driving investigations into a variety of therapeutic strategies for Lafora disease, including reduction in brain glycogen synthesis and replacement of the non-functional gene.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41582-018-0057-0

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 167

Metadata

Authors
Nitschke, F., Ahonen, S. J., Nitschke, S., Mitra, S., & Minassian, B. A.
Venue
Nature Reviews Neurology
Published
2018-08-24
Volume
14
Issue
10
Pages
606-617
ISSN
  • 1759-4758 (ISSN-L)
  • 1759-4766
OpenAlex
W2888224568
Cited by
167
References
22
FWCI
2.94
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lafora disease — from pathogenesis to treatment strategies. https://app.cochat.ai/papers/10.1038/s41582-018-0057-0
The paper
Nitschke, F., Ahonen, S. J., Nitschke, S., Mitra, S., & Minassian, B. A. (2018). Lafora disease — from pathogenesis to treatment strategies. Nature Reviews Neurology. https://doi.org/10.1038/s41582-018-0057-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.